Aaron S. Farberg, MD, and Jeffrey Crowley, MD, share take-home messages on the impact of the generalized pustular psoriasis study.
Ethan Sims, MD, spoke with Dermatology Times on having positive conversations, cutting down on waste, and how to get involved in change.
Spherix Global Insights recently delved into the efficacy, patient quality of life, and symptom management of adalimumab vs secukinumab.
Program Chair Jay A. Lieberman, MD, provides a glimpse into the clinical pearls and dermatological educational opportunities presented at the ACAAI 2023 Annual Scientific Meeting.
“Edward” is a 35-year-old Hispanic male presenting with a new rash on the buttocks which has been present for approximately 1 month.
A 5-expert panel continues their conversation on atopic dermatitis, discussing patient-centered care and key takeaways.
Alexa Hetzel, MS, PA-C; Jennifer Conner, MPAS, PA-C; Terry Faleye, MPAS, PA-C; Laura Bush, DMSc, PA-C; and Lakshi Aldredge, MSN, ANP-BC, share take-home messages regarding the treatment of patients with plaque psoriasis, highlighting listening to and educating patients.
Technology and care navigators are key to managing this growing population
Recent studies show patients are experiencing adverse effects of stopping corticosteroid treatment.
Experts detail 5 tips to ask a financial advisor so they can best serve your interests.
James Del Rosso, DO, continues the discussion on managing acne in a female patient, emphasizing how to balance patient expectations and optimize skincare regimens, particularly when underlying conditions like polycystic ovarian syndrome are present.
Session at the American College of Allergy, Asthma and Immunology (ACAAI) 2023 Annual Scientific Meeting explored issues in understanding and testing for physical urticaria.
Papp shared insights from the recent STRIDE phase 2 trial, which met all its primary and secondary endpoints. Data was presented at the American Academy of Dermatology Annual Meeting.
James Song, MD, shares a comprehensive guide to what is new, what is now, and what is next in AD treatment.
Iltefat Hamzavi, MD, discusses the REGINA 007 phase 2 trial evaluating MK-6194 for the treatment of non-segmental vitiligo.
For years, teenagers have been told to avoid certain foods to reduce acne. A review article examines the evidence.
Argyria is a rare dermatologic condition that presents with blue or grey mucocutaneous discoloration following cutaneous exposure or ingestion of silver.
Reynolds discussed what attendees need to know about using cemiplimab to target their difficult skin cancer patients at the Fall Clinical Dermatology Conference for PAs and NPs.
Rob Casquejo, PA-C, spoke with Dermatology Times on new and upcoming medications, addressing unmet needs, and social media misinformation.
Melinda Gooderham, MSc, MD, FRCPC, discusses potential new biologics for atopic dermatitis that target IL-22, IL-33, OX40, and more.
Answers to some common questions about providing telehealth services in 2023.
Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, review the study results for the ADORING 1 and ADORING 2 trials, as well as share closing thoughts on the use of tapinarof in management of AD.
Ablon’s session highlights include best practices for hair restoration.
Get a sneak peek ahead of AAD about the LITE study’s patient-centered design, routine care integration, and diverse participant inclusion, offering a cost-effective option in psoriasis treatment.
Rick Guidotti, fashion photographer turned patient advocate, discusses reframing beauty through his nonprofit Positive Exposure.